TY - JOUR
T1 - The ability of biomarkers to assess the severity of atopic dermatitis
AU - Nakahara, Takeshi
AU - Onozuka, Daisuke
AU - Nunomura, Satoshi
AU - Saeki, Hidehisa
AU - Takenaka, Motoi
AU - Matsumoto, Mai
AU - Kataoka, Yoko
AU - Fujimoto, Rai
AU - Kaneko, Sakae
AU - Morita, Eishin
AU - Tanaka, Akio
AU - Saito, Ryo
AU - Okano, Tatsuro
AU - Miyagaki, Tomomitsu
AU - Aoki, Natsuko
AU - Nakajima, Kimiko
AU - Ichiyama, Susumu
AU - Kido-Nakahara, Makiko
AU - Tonomura, Kyoko
AU - Nakagawa, Yukinobu
AU - Tamagawa-Mineoka, Risa
AU - Masuda, Koji
AU - Takeichi, Takuya
AU - Akiyama, Masashi
AU - Ishiuji, Yozo
AU - Katsuta, Michie
AU - Kinoshita, Yuki
AU - Tateishi, Chiharu
AU - Yamamoto, Aya
AU - Morita, Akimichi
AU - Matsuda-Hirose, Haruna
AU - Hatano, Yutaka
AU - Kawasaki, Hiroshi
AU - Fukushima-Nomura, Ayano
AU - Ohtsuki, Mamitaro
AU - Kamiya, Koji
AU - Kabata, Yudai
AU - Abe, Riichiro
AU - Mitsui, Hiroshi
AU - Kawamura, Tatsuyoshi
AU - Tsuji, Gaku
AU - Katoh, Norito
AU - Furue, Masutaka
AU - Izuhara, Kenji
N1 - Publisher Copyright:
© 2023 The Author(s)
PY - 2024/2
Y1 - 2024/2
N2 - Background: To develop precision medicine for atopic dermatitis (AD), it is critical to establish relevant biomarkers. However, the characteristics of various biomarkers have not been fully understood. We previously carried out the Biomarkers to Predict Clinical Improvement of AD in Patients Treated with Dupilumab (B-PAD) study, a comprehensive nationwide study in Japan, to explore biomarkers for AD. Objective: The aim of this study is to find biomarkers associated with objective and subjective clinical findings in patients with moderate-to-severe AD based on the B-PAD study and to identify biomarkers sensitive enough to assess the severity of AD. Methods: We performed the B-PAD study as a consortium composed of 19 medical facilities in Japan, enrolling 110 patients with moderate-to-severe AD. We evaluated the Eczema Area and Severity Index (EASI) for objective assessment as well as the Patient-Oriented Eczema Measure (POEM) and a numeric rating scale for pruritus (pruritis-NRS) for subjective assessment, measuring 19 biomarkers at baseline. Results: We found that 12, 6, and 7 biomarkers showed significant and positive associations with the EASI, POEM, and pruritis-NRS, respectively. Most of the biomarkers associated with either the POEM or the pruritis-NRS were included among the biomarkers associated with EASI. Of the biomarkers examined, CCL26/eotaxin-3 and SCCA2 were the most capable of assessing severity for EASI, as shown by the 2 kinds of receiver operating characteristic analyses, respectively, whereas lactate dehydrogenase was the best for both the POEM and pruritis-NRS, again using the 2 analyses. Conclusion: We found biomarkers associated with the EASI, POEM, and pruritis-NRS, respectively, based on the B-PAD study. Moreover, we identified CCL26/eotaxin-3 and/or SCCA2 as the biomarkers having the greatest ability to assess severity in the EASI; lactate dehydrogenase did the same for the POEM and pruritis-NRS. These findings will be useful in treating patients with moderate-to-severe AD.
AB - Background: To develop precision medicine for atopic dermatitis (AD), it is critical to establish relevant biomarkers. However, the characteristics of various biomarkers have not been fully understood. We previously carried out the Biomarkers to Predict Clinical Improvement of AD in Patients Treated with Dupilumab (B-PAD) study, a comprehensive nationwide study in Japan, to explore biomarkers for AD. Objective: The aim of this study is to find biomarkers associated with objective and subjective clinical findings in patients with moderate-to-severe AD based on the B-PAD study and to identify biomarkers sensitive enough to assess the severity of AD. Methods: We performed the B-PAD study as a consortium composed of 19 medical facilities in Japan, enrolling 110 patients with moderate-to-severe AD. We evaluated the Eczema Area and Severity Index (EASI) for objective assessment as well as the Patient-Oriented Eczema Measure (POEM) and a numeric rating scale for pruritus (pruritis-NRS) for subjective assessment, measuring 19 biomarkers at baseline. Results: We found that 12, 6, and 7 biomarkers showed significant and positive associations with the EASI, POEM, and pruritis-NRS, respectively. Most of the biomarkers associated with either the POEM or the pruritis-NRS were included among the biomarkers associated with EASI. Of the biomarkers examined, CCL26/eotaxin-3 and SCCA2 were the most capable of assessing severity for EASI, as shown by the 2 kinds of receiver operating characteristic analyses, respectively, whereas lactate dehydrogenase was the best for both the POEM and pruritis-NRS, again using the 2 analyses. Conclusion: We found biomarkers associated with the EASI, POEM, and pruritis-NRS, respectively, based on the B-PAD study. Moreover, we identified CCL26/eotaxin-3 and/or SCCA2 as the biomarkers having the greatest ability to assess severity in the EASI; lactate dehydrogenase did the same for the POEM and pruritis-NRS. These findings will be useful in treating patients with moderate-to-severe AD.
KW - Atopic dermatitis
KW - B-PAD
KW - biomarker
KW - Biomarkers to Predict Clinical Improvement of AD in Patients Treated With Dupilumab
KW - EASI
KW - eotaxin-3
KW - LDH
KW - POEM
KW - precision medicine
KW - pruritus-NRS
KW - SCCA2
UR - https://www.scopus.com/pages/publications/85174464010
UR - https://www.scopus.com/pages/publications/85174464010#tab=citedBy
U2 - 10.1016/j.jacig.2023.100175
DO - 10.1016/j.jacig.2023.100175
M3 - Article
AN - SCOPUS:85174464010
SN - 2772-8293
VL - 3
JO - Journal of Allergy and Clinical Immunology: Global
JF - Journal of Allergy and Clinical Immunology: Global
IS - 1
M1 - 100175
ER -